CorFlow Therapeutics
SwitzerlandEntry
2024
Hold
2yr
Status
Active
Who owns CorFlow Therapeutics?
CorFlow Therapeutics is currently owned by 415 Capital Management through 415 Capital Fund II (2024 vintage), since 2024. Across its history, CorFlow Therapeutics has been through 3 private equity ownership periods, detailed in the timeline below.
Hand-verified · updated 2026-07-23
Most recent investor
415 Capital Management415 Capital Fund II · 2024 · VC
3 ownership periods · full history below
Key facts
Ownership history
3 ownership periods · co-invest detected
Active
Co-invest · 3 holders · 2024 · present
Wellington PartnersActive
2024 · present(2yr) · Wellington Partners Life Sciences · 1998 · VC
415 Capital ManagementActive
2024 · present(2yr) · 415 Capital Fund II · 2024 · VC
Panakes Partners SGRActive
2024 · present(2yr) · Panakes Fund Purple · 2021 · Life Sciences VC
More from 415 Capital Fund II
Other portfolio companies in the same fund.
USMore 415 Capital Management portfolio companies
From the same investor, across funds.
Germany
More PE-backed in MedTech
Comparable medtech deals from other GPs.
Track CorFlow Therapeutics
Save this record to your watchlist and pick up your research where you left off. No spam.
Who could buy CorFlow Therapeutics?
7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.
Find likely buyersGet the full record on CorFlow Therapeutics.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
Already a member? Sign in
Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue